Biomarker Integration for Advanced Urothelial Carcinoma
Dr. Donna E. Hansel, MD, PhD delves into the critical role of biomarker integration in the management of advanced urothelial carcinoma.
Read MoreSelect Page
Donna E. Hansel, MD, PhD, is the Division Head of Pathology and Laboratory Medicine at the University of Texas MD Anderson Cancer Center in Houston, Texas. Previously, Dr. Hansel served as the Chair of Pathology at Oregon Health & Science University (OHSU) in Portland, Oregon. In 2013, Dr. Hansel was appointed Professor of Pathology and Chief of the Division of Anatomic Pathology at the University of California, San Diego. Dr. Hansel joined the Cleveland Clinic Anatomic Pathology Staff as Assistant Professor in 2006 as a subspecialty genitourinary pathologist and was promoted to Associate Professor in 2010.
Dr. Hansel completed a bachelor of science degree in biology at Johns Hopkins University, graduating Phi Beta Kappa. She subsequently completed the MD-PhD Medical Scientist Training Program, pathology residency, and urologic pathology fellowship at the Johns Hopkins University School of Medicine.
Dr. Hansel has authored over 170 peer-reviewed publications, edited or authored five textbooks on urologic pathology and biospecimen repositories, and participated in more than 100 national or international talks on bladder cancer. She has participated in the kidney-urinary tract panel for the 8th Edition Cancer Staging Manual of the American Joint Committee on Cancer (AJCC) and contributed to the 5th edition of the WHO Classification of Tumours of the Urinary System and Male Genital Organs. In addition, Dr. Hansel is on the editorial board of the American Journal of Surgical Pathology, Advances in Anatomic Pathology, American Journal of Pathology, Histopathology, and Archives of Pathology & Laboratory Medicine where she serves as Deputy Executive Editor. Dr. Hansel has mentored over 40 residents, graduate students, and postdoctoral fellows while remaining active in clinical science and overseeing a research laboratory focused on invasive cancer mechanisms.
Posted by Donna E. Hansel, MD, PhD | Dec 2022
Dr. Donna E. Hansel, MD, PhD delves into the critical role of biomarker integration in the management of advanced urothelial carcinoma.
Read MorePosted by Donna E. Hansel, MD, PhD | Dec 2022
Dr. Donna E. Hansel, MD, PhD discusses molecular pathology in clinical practice and urothelial cancer treatment.
Read MorePosted by Donna E. Hansel, MD, PhD | Dec 2022
Dr. Donna E. Hansel, MD, PhD, addresses micropapillary and standard forms of bladder cancer, characteristics and treatment.
Read MorePosted by Donna E. Hansel, MD, PhD | Dec 2022
Donna E. Hansel, MD, PhD delves into the molecular and genetic differences that define Upper tract urothelial carcinoma (UTUC).
Read More